

**Complicated Cataract Cases Update (1/7/2023 @ 8 a.m. ET)**

**Saturday, January 7, 2023**

*Wills Eye Auditorium*

**[Conference Description:](https://attendee.gotowebinar.com/register/6984656836561632012%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

[Register for Livestream Reminders Here!](https://attendee.gotowebinar.com/register/6984656836561632012%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://attendee.gotowebinar.com/register/6984656836561632012%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

**At the conclusion of the course, participants should be able to:**

1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of cataracts in complicated cases involving other eye disease.

2 Identify basic and clinical vision research that can be transformed into improved clinical care.

3 Assess the role of new technologies in the evaluation and treatment of eye diseases.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**MOC Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning, Self-Assessment, Improvement in Medical Practice and/or Patient Safety requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Ethan C Heck, MD | Activity Coordinator | Nothing to disclose - 11/03/2022 |
| Shaunna Lee, MD | Activity Coordinator | Nothing to disclose - 10/12/2022 |
| Mark Blecher, MD | Faculty | Consulting Fee-Johnson & Johnson - 02/09/2022 |
| Kristin DiDomenico, MD | Faculty | Consulting Fee-Santen Pharmaceuticals (Relationship has ended) - 12/20/2022 |
| John Epstein, MD | Faculty | Nothing to disclose - 02/09/2022 |
| Omesh P. Gupta, MD, MBA | Faculty | Nothing to disclose - 11/20/2022 |
| Sadeer B. Hannush, MD | Faculty | Consulting Fee-Kowa, Inc - 01/06/2023 |
| Alessandra Intili, MD | Faculty |  |
| Marlene R. Moster, MD | Faculty | Speakers Bureau-Aerie Pharmaceuticals|Grant or research support-Alcon|Grant or research support-Santen Pharmaceuticals|Grant or research support-Nicox|Grant or research support-Glaukos Corporation|Grant or research support-Allergan|Speakers Bureau-Bausch + Lomb - 11/10/2022 |
| Sagun Pendse, MD | Faculty | Nothing to disclose - 12/20/2022 |
| Mark F Pyfer, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson (Relationship has ended)|Paid consultant-Johnson & Johnson|Independent Contractor (included contracted research)-Sight Sciences|Speakers Bureau-Sight Sciences|Speakers Bureau-Rayner Surgical|Independent Contractor (included contracted research)-Tarsus (Relationship has ended) - 12/11/2022 |
| Richard Tipperman, MD | Faculty | Advisor-Alcon - 12/07/2022 |
| Sydney Tyson, MD | Faculty | Nothing to disclose - 12/18/2022 |
| Douglas Wisner, MD | Faculty | Advisor-Zeiss|Advisor-Haag-Streit - 03/25/2022 |
| Robert S Bailey, MD | Faculty, Planner | Nothing to disclose - 02/05/2022 |
| Robert Lehman, MD | Faculty, Planner | Nothing to disclose - 02/11/2022 |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Stocks or stock options, excluding diversified mutual funds-Merck - 06/07/2022 |

